Summary
Studies with a 3′-branched chain homolog (α-3′-BCTGdR) of 2′-deoxythioguanosine (α-TGdR) showed that it did not prolong the survival of mice bearing the Mecca lymphosarcoma. Host toxicity was quite profound and resembled that seen with 6-thioguanine (6-TG). Evidence was obtained that this nucleoside derivative was not appreciably converted to 6-TG in the mouse. Mice treated with toxic doses of 6-TG or α-3′-BCTGdR were found to have very similar pathological changes. The granulocytes were eliminated from the peripheral blood, bone marrow was acellular, and some more limited damage was seen in the intestinal crypts. Experiments with radiosulfur-labeled drugs demonstrated that α-3′-BCTGdR was incorporated into the DNA of mouse bone marrow, predominantly in the chain-terminating position, with the result that shorter chains of DNA accumulated. The new homolog, unlike α-TGdR, was phosphorylated in bone marrow as well as in tumor, and incorporated well into the DNA both of bone marrow and of the neoplastic cells. In devising other homologs attention must be given to the specificity of the kinases, i.e., to whether phosphorylation is superior in tumor cells or in the growing normal cells.
Similar content being viewed by others
Abbreviations
- 6-TG:
-
6-thioguanine
- α,β-TGdR:
-
α,β-2′-deoxythioguanosine
- α-3′-BCTGdR:
-
6-thioguanine-α-2,3-dideoxy-3-(hydroxymethyl)-d-erythro-pentofuranose
- 3H-TdR:
-
Tritium-labeled (methyl) thymidine
References
Acton EM, Goerner RN, Uh HS, Ryan KH, Henry DW, Cass CE, LePage GA (1979) Improved antitumor effects in 3′-branched homologues of 2′-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-4-(hydroxymethyl)-d-erythro-pentofuranose. J Med Chem 22: 518–525
Jacobsen W, Webb M (1952) The two types of nucleoproteins during mitosis. Exp Cell Res 3: 163–183
LePage GA (1963) Basic biochemical effects and mechanisms of action of 6-thioguanine. Cancer Res 23: 1202–1206
LePage GA (1968) Metabolism of α-2′-deoxythioguanosine in murine tumor cells. Can J Biochem 46: 655–661
LePage GA, Junga IG (1967) The utilization of α-2′-deoxythioguanosine by murine tumor cells. Mol Pharmacol 3: 37–43
LePage GA, Khaliq A (1979) Pharmacology and toxicology of α-2′-deoxythioguanosine in cancer patients. Cancer Chemother Rep 63: 53–57
Omura GA, Vogler WR, Smalley RV, Maldonado N, Brown GO, Knospe WH, Ahn YS, Faguet GB (1977) Phase II study of β-2′-deoxythioguanosine in adult acute leukemia. Cancer Chemother Rep 61: 1379–1381
Sartorelli AC, LePage GA (1957) Modification of thioguanine toxicity in tumor-bearing mice with bone marrow transplants. Proc Am Assoc Cancer Res 2: 246
Tamaoki T, LePage GA (1975) Inhibition of DNA chain growth by α-2′-deoxythioguanosine. Cancer Res 35: 1015–1017
Walters RA, Hildebrand CE (1975) A procedure for the rapid lysis of mammalian cells prior to alkaline sucrose density gradient cetrifugation. Biochim Biophys Acta 407: 120–124
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
LePage, G.A., Banks, P.A., Noujaim, M.J. et al. In vivo effects in mice produced by a 3′-branched homologue of α-2′-deoxythioguanosine. Cancer Chemother. Pharmacol. 5, 127–131 (1980). https://doi.org/10.1007/BF00435416
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00435416